Purpose: Review and discuss medications efficacious for seizure control, despite primary indications for other diseases, as treatment options in patients who have failed therapy with traditional antiepileptic drugs (AEDs). Methods: Literature searches were conducted utilizing PubMed and MEDLINE databases employing combinations of search terms including, but not limited to, "epilepsy", "refractory", "seizure", and the following medications: acetazolamide, amantadine, bumetanide, imipramine, lidocaine, verapamil, and various stimulants. Results: Data from relevant case studies, retrospective reviews, and available clinical trials were gathered, analyzed, and reported. Experience with acetazolamide, amantadine, bumetanide, imipramine, lidocaine, verapamil, and various stimulants show promise for cases of refractory epilepsy in both adults and children. Many medications lack large scale, randomized clinical trials, but the available data is informative when choosing treatment for patients that have failed traditional epilepsy therapies. Conclusions: All neurologists have encountered a patient that failed nearly every AED, diet, and surgical option. For these patients, we often seek fortuitous discoveries within small series and case reports, hoping to find a treatment that might help the patient. In the present review, we describe medications for which antiepileptic effect has been ascribed after they were introduced for other indications.
Introduction
Several antiepileptic drugs (AEDs) have been discovered by happenstance, often uncovering their efficacy in the course of use for other indications. Phenobarbital, originally introduced as a hypnotic, was used by Alfred Hauptmann in 1912 in an effort to help his patients with epilepsy get a better night's sleep. Seizure incidence and intensity were reduced leading him to ascribe antiseizure properties to the drug [1] . Valproic acid's (VPA) anticonvulsant properties were fortuitously discovered in 1962 by Pierre Eymard and colleagues who used VPA as a solvent to dissolve other water-insoluble compounds. After finding nearly all compounds tested well in the pentylenetetrazole seizure test, they ultimately attributed the anticonvulsant effect to the solvent [2] . Similar discoveries have continued over time. Drugs originally marketed for other indications have found use in epilepsy -coincidentally or intentionally -because of their mechanism of action (MOA). While these discoveries are rare, large scale studies and published reports are even more elusive. All neurologists have encountered a patient that failed nearly every AED, diet, and surgical option, often seeking out small series and case reports hoping to find one more treatment that might help the patient. In the present review, we describe a number of medications for which antiepileptic effect has been ascribed after introduction for other indications (Table 1) . We further summarize pharmacokinetics, adverse effects, and potential interactions with concomitant drugs to help guide their use (Table 2) .
Abbreviations: AE, adverse effect; AED, antiepileptic drug; AP, action potential; ADHD, attention-deficit/hyperactivity disorder; BBB, blood brain barrier; CAI, carbonic anhydrase inhibitor; CNS, central nervous system; EEG, electroencephalogram,; FDA, U.S. Food and Drug Administration; GABA, gamma-aminobutyric acid; GTC, generalized tonic-clonic; GX, glycinexylidide; HASS, Hague Seizure Severity Scale; IV, intravenous; LGS, Lennox Gastaut Syndrome; MOA, mechanism of action; MEGX, monoethylglycinexylidide; NE, norepinephrine; NMDA, N-methyl-D-aspartate; NKCC, Na
À co-transporter; P-gp, P-glycoprotein; RNA, ribonucleic acid; SLE, seizure-like event; SMEI, severe myoclonic epilepsy of infancy; SE, status epilepticus; VPA, valproic acid.
Acetazolamide
Acetazolamide is a nonbacteriostatic sulfonamide and carbonic anhydrase inhibitor (CAI). Carbonic anhydrase catalyzes the reversible reaction of carbon dioxide hydration (CO 2 ) and carbonic acid dehydration (HCO 3 À ). Acetazolamide directly inhibits carbonic anhydrase, resulting in a diuretic effect, urine alkalization, and slowing of abnormal, paroxysmal, and excessive discharge from central nervous system (CNS) neurons. The wide range of effects has resulted in multiple U.S. Food and Drug Administration (FDA) approved indications (i.e. adjunctive treatment of edema, glaucomas, altitude sickness) [3] . Most notable is the indication for centrencephalic epilepsies described by Penfield and Jasper to include absence, myoclonic, akinetic and major seizures with electroencephalogram (EEG) showing bisynchronous spike wave at or near 3Hz [4] .
The exact antiepileptic modality of acetazolamide is not precisely known. Proposed processes include direct inhibition of carbonic anhydrase in the CNS resulting in reduced bicarbonate accumulation in neurons and attenuation of action potential (AP) firing. When aberrant AP firing is dampened, seizure activity is reduced or eliminated [5, 6] . Antiepilepticeffects of acetazolamide may also result from the slight degree of acidosis achieved when the dose is divided [4] . CAIs may exert seizure control through gamma-aminobutyric acid (GABA)-mediated mechanisms. Limitation of HCO 3 À efflux from GABA channels may also increase the efficacy of GABA-mediated inhibition. This presents the opportunity to concomitantly increase antiepileptic efficacy with GABAergic activity and to directly dampen seizure activity [7, 8] .
Acetazolamide may, in part, possess an antiepileptic mechanism similar to topiramate and zonisamide which also exhibit a CAI mechanism [4, 9] . Topiramate and zonisamide can attribute part of their antiepileptic mechanism to carbon dioxide equilibrium disruption and/or the inhibition of ion channels [9] . Acetazolamide has reported efficacy in multiple seizure types including generalized tonic-clonic (GTC), absence, myoclonic, and mixed seizure patterns. In one of the earliest reports, 26 patients with various idiopathic epilepsies were treated with acetazolamide 3 to 14 mg/kg divided twice daily. Approximately 53% experienced an excellent or good response. Another 31% experienced some therapeutic value. Ansell et al. noted need for increased dosage throughout therapy, perhaps an early report of tolerance with long term acetazolamide use [10] .
Forsythe et al. examined 54 pediatric patients with carbamazepine-resistant grand mal seizures treated with acetazolamide 10 mg/kg/day [11] . At two-year follow-up, 16 of 40 patients (40%) had achieved complete remission of grand mal seizures, 7 (18%) reached 75% reduction, and one (3%) achieved 50% reduction. In 14 patients with temporal lobe seizures, complete remission was seen in seven (50%), and 75% reduction was seen in two (14%) others [11] . Another 48 patients with refractory partial seizures were retrospectively reviewed. Initial adjunct acetazolamide ranged from 3 to 6 mg/kg/day and were titrated up to maintenance (range 3.8 to 22 mg/kg/day) based on clinical response and side effects. Therapy duration ranged from 1.5 to 30 months. Ultimately, 21 of 48 (43%) patients responded with at least 50% reduction in seizures within the first 3 months. With dose increases, cumulative percent responders was nearly 80% by study's end with average response duration of 12.9 months (range: 3-30 months) [12] . Finally, a pediatric patient with intractable atypical absence seizures appeared to temporarily respond to concomitant acetazolamide (20 mg/kg/day), ethosuximide, and adrenocorticotropic hormone showing improved EEG results [13] .
Two factors may play an important role in efficacy at initiation and maintenance of therapy with acetazolamide: age and physiologic tolerance. Animal studies demonstrate an inherent pharmacoresistance in very immature hippocampal-entorhinal region tissues; response appears to improve with increasing age [5] . Several studies report need for increased dosages over timemost likely due to tolerance with long term use [12, 14, 15 ].
Acetazolamide's place in therapy cannot be assessed without considering potential risks and side effects. Concomitant use of agents with CAI activity (i.e. phenytoin, phenobarbital, topiramate, zonisamide) presents risk of hyperammonemia [16] . Studies report minimal side effects -mostly dose related (i.e. paresthesias, electrolyte changes, lethargy, kidney stones, metabolic acidosis, appetite suppression, and blood dyscrasias) [10, 12, 15] . When used to treat epilepsy, 20-40% of patients reported mild dose related side effects [10, 11] . Acetazolamide has been used effectively for decades in the treatment of epilepsy. Studies suggest efficacy in focal and generalized seizure types. Effective dosages appear to range from 3 to 22 mg/kg/day, adjusting for patient response and side effects. Tolerance and age may play roles in efficacy but should not preclude use. Addition of acetazolamide in patients with preexisting acidosis or electrolyte abnormalities may be amplified, but overall, acetazolamide appears safe and efficacious for seizure management.
Amantadine
The tricyclic amine amantadine is currently FDA approved in the treatment of Parkinson's disease, drug-induced extrapyramidal disorders, and influenza A prophylaxis [17, 18] . Its antiviral indication correlates to anti-ribonucleic acid (RNA) activity blocking penetration of the virus into respiratory epithelial host cells and blocking the uncoating of the virus and release of nucleic acids [18, 19] . Anti-Parkinsonian activity is not precisely known; data suggests amantadine directly and indirectly affects dopamine. Pre-synaptically, amantadine enhances dopamine release and inhibits its reuptake [17, 20] . Post-synaptically, in vivo studies show direct upregulation of D2 receptors [17, 21] . Amantadine's anti- Parkinsonian action may also be attributed to weak, noncompetitive N-methyl-D-aspartic acid (NMDA) receptor antagonism [18] . Amantadine's antiepileptic effects, like its anti-Parkinsonian activity, are not clearly defined yet appear to be multifactorial. Dopamine pathways appear to play essential roles in modulating the presence or dissipation of absence seizures. For example, D 1 and D 2 agonists have reduced spike-wave durations in animal absence epilepsy models [22, 23] . Antiepileptic activity has also been attributed to NMDA antagonism. This may suppress thalamocortical oscillary activity ultimately suppressing the spike wave discharges that cause the seizure activity [24] . Studies suggest the amantadine precursor, 1-aminoadamantane, may also act as an NMDA-receptor antagonist which is synergistic to MK-801 (binding site of the excitatory NMDA-receptor gated ion channel). Reduced calcium-channel membrane current consequently diminishes intracellular calcium ion influx, perhaps producing anticonvulsive results [25] [26] [27] .
Amantadine may be especially useful in treatment of absence, and, to some extent, myoclonic seizures. Shields et al. reported one of the first commentaries of amantadine's anticonvulsant effects in seizure treatment. Ten patients were given amantadine 6 to 8 mg/ kg/day divided twice daily and followed over 8 weeks. Among 10 subjects, five different seizure types were present: atypical absence (4); myoclonic (7); tonic (2); atonic (3); and tonic-clonic (4). All patients with atypical absence seizures experienced response rates determined to be good or excellent (50 to 90% or greater). Similar results were reported for patients with myoclonic seizures. Of the others, five were determined to have good or excellent responses with only two failing to respond (<50% reduction, but no increase in frequency or severity). Conversely, tonic, atonic, and tonic-clonic seizures appeared to show no response or worsen [28] .
Shahar et al. corroborated these findings in a small study of four patients with refractory absence epilepsy receiving amantadine 5 to 7 mg/kg/day (maximum 200 mg/day) [25] . All four patients experienced complete resolution of seizure activity within the first week of treatment and remained symptom free without side effects for 24 to 36 months [25] . Earlier studies indicated amantadine's potential to increase adjuvant AED serum concentrations, yet this study did not corroborate those findings [29] . In fact, no adjuvant AED serum concentrations (particularly VPA or phenytoin) were altered at any point in the study [25] .
Recent studies have strengthened these early findings. A retrospective review of 13 patients by Perry et al. saw a nearly 67% initial success rate with amantadine in the treatment of children with refractory absence epilepsy [30] . Concomitant AEDs were optimized prior to amantadine initiation, and amantadine dosing was titrated to a goal of 4 to 7 mg/kg/day (maximum 200 mg/day). AED doses were not adjusted during application of amantadine. Treatment response was measured by parental accounts and analyzed at three, six, and 12 months after treatment initiation [30] . At 12 months, 58% of patients maintained response rates of at least 50% seizure reduction with the majority (nearly 86%) of responders sustaining greater than 90% seizure reduction. Four patients reported adverse effects (AEs) -included vomiting, behavioral changes, headache, dizziness, and weight loss. Vomiting was therapy limiting for one patient. No renal, hepatic, or hematologic toxicity were noted -a favorable and unique attribute in the spectrum of current AED options [30] .
Overall, the use of amantadine for refractory absence epilepsy has been promising in available literature. Similar dosing profiles of 4 to 8 mg/kg/day (maximum 200 mg/day) could make addition of amantadine to optimized AED regimens for refractory absence epilepsy quite generalizable [25, 27, 30] . Nonetheless, large, multicenter controlled trials have not yet been conducted to examine the use of amantadine for this indication. However, the relatively safe profile, straightforward dosing, and efficacious results reported in studies over the last three decades should be encouraging to consider amantadine as an adjuvant treatment in cases of refractory absence epilepsy.
Bumetanide
Bumetanide, a loop diuretic, is commonly utilized to treat edema associated with congestive heart failure, hepatic disease, and renal disease, including nephrotic syndrome. Its diuretic MOA is attributed to luminal Na
blockade located in the thick ascending limb of the loop of Henle. Proximal tubule action is altered as well, and the combination of mechanisms results in diuresis [31, 32] . Notably, NKCC2 is exclusively located in the kidney while NKCC1 is found throughout the body (i.e. stomach, heart, skeletal muscle, lungs, kidney, and brain) [33] [34] [35] ].
Bumetanide's antiepileptic effect is not as defined as its diuretic effect. Several brain disorders have been linked to the functionality of NKCC1. Much interest has focused on epilepsy, particularly neonatal seizures [35] . When expressed in the brain, NKCC1 is chiefly expressed on plasma membranes of pyramidal cells in the cerebral cortex, striatum, hippocampus, dorsal root ganglia of the spinal cord, and glial cells [35] [36] [37] [38] . When trauma is presented in the neonatal brain, NKCC1 is upregulated, chloride ion currents are reversed, and GABAa is depolarized [39] . Increased depolarization upon excessive activation of GABAa receptors leads to neuronal hyperexcitability (especially during an early developmental stage), further potentiating seizure activity. Recurrent seizures in neonates may progressively increase intracellular chloride ions and the probability of additional seizures [40] . Intracellular chloride ion accumulation and GABA depolarization may be avoided via bumetanide NKCC1 blockade [35] .
Age appears to affect bumetanide response. Animal studies demonstrated varied responses in different hippocampal-entorhinal regions when various ages were selected [41] . Additionally, while primarily inhibitory responses in adults, GABA switches to produce excitatory results in patients at an early developmental stage presenting a potential mechanism for seizure treatment [35, 42, 43] . Eftekhari et al. described success with bumetanide in three adult patients with medication-resistant temporal lobe seizures [44] . Subjects were assigned to bumetanide 2 mg/day; results were monitored via changes in number of seizure-free days during the four month study period. All patients had reduced seizures (68-84%) after treatment over the four month treatment [44] .
Kahle et al. applied bumetanide in the treatment of a six weekold neonate with EEG confirmed multifocal seizures refractory to multiple AEDs [45] . Significant reduction in mean seizure frequency (from 36 AE 7 to 21 AE7 seizures/hour; p = 0.02, a = 0.05) and duration (from 17.32 to 14.44 s; p = 0.024, a = 0.05) were noted on continuous EEG monitoring with bumetanide. Mean spike frequency decreased from 3.85 Hz to 3.23 Hz (p = 0.02, a = 0.05). No side effects (i.e. dehydration, hypotension, renal failure, azotemia, ototoxicity, etc.) or metabolic imbalances were reported [45] .
Other studies report efficacy combining bumetanide and phenobarbital in a neonatal seizure model. Dzhala et al. and Nardou et al. reported similar findings with in vitro models of hippocampal preparations finding bumetanide prior to phenobarbital efficiently reduces seizure severity -perhaps due to alterations of chloride ion transport allowing improved phenobarbital efficacy [46, 47] .
Not all data substantiates utilization of bumetanide for seizure treatment. Brandt et al. used bumetanide infusions of 0.8 mg/kg/h concomitantly with phenobarbital for pilocarpine induced temporal lobe epilepsy in female rats. No adequate antiepileptic effect was seen nor was phenobarbital's action potentiated with coadministration [48] . No efficacy in neonatal seizure secondary to hypoxic ischemic encephalopathy was seen with concomitant bumetanide and phenobarbital in the 2015 multicenter trial by Pressler et al. [49] . Fourteen infants received at least one dose of bumetanide; doses ranged from 0.05 to 0.3 mg/kg [49, 50] . Three of 11 surviving infants had hearing impairment, one subject withdrew due to dehydration, and several infants experienced hypotension and/or electrolyte disturbances. The trial was stopped early given serious AEs (i.e. ototoxicity; coagulopathy and multiorgan failure secondary to hypoxic ischemic encephalopathy) and limited evidence for seizure reduction [49, 50] . Shein et al. administered intravenous (IV) bumetanide 0.1 mg/kg/dose every eight hours to treat status epilepticus (SE) in a four month-old infant with SCN1A mutation [51] . The infant was unresponsive to multiple medications and bumetanide did not produce significant change in seizure pattern [51] . As others have noted, these results are not indicative of patients in all situations and, more specifically, cannot be extrapolated to other seizure types [50] .
Finally, bumetanide may play a role in preventing epileptogenic processes that occur after SE via remodeling of aberrant glutaminergic neuronal circuits caused by early post SE evoked chloride dysregulation. Kourdougli et al. examined the immunohistochemistry of NKCC1, NKCC2, and ectopic recurrent mossy fiber sprouting in the presence of bumetanide [52] . With the introduction of bumetanide, chloride homeostasis was normalized and glutamatergic recurrent mossy fiber sprouting was reduced. They concluded bumetanide is promising in the early post-SE stage to impede reactive glutamatergic network rewiring [52] . Similarly, Sivakumaran et al. demonstrated efficacy with bumetanide in kainic acid-induced SE in vivo and 0-Mg(2+)-induced seizure-like events in vitro [53] . Their data suggested a role for chloride plasticity in the progression of seizures and that if seizure progression is controlled early on, this could implicate chloride plasticity in the development or the control in pharmacoresistant SE [53] .
Bumetanide data has produced conflicting results on efficacy as an AED, but derivatives with higher NKCC1 selectivity may be more successful [54] . Bumetanide is highly plasma protein bound and has high rates of ionization. These may restrict brain entry and affect efficacy in seizure therapy. Probenecid has been shown to markedly increase bumetanide's plasma half-life and could be utilized concomitantly to increase bumetanide's concentration in the brain [55] . Lipophilic, uncharged prodrugs of bumetanide have been examined to increase bumetanide's efficacy. Thus far, there has been data demonstrating significantly higher brain concentrations of bumetanide with prodrug administration compared to parent drug administration. More research is warranted to determine safety and efficacy [56] .
Bumetanide for seizure treatment presents unique opportunities yet conflicting data. Practitioners must practice caution, weigh risks and benefits, and individualize therapy when considering bumetanide. In the interim, bumetanide may provide a short term option to better control seizures and seizure severity in temporal lobe and neonatal seizures.
Imipramine
Tricyclic antidepressants are integral in treatment of many neurologic diagnoses. Imipramine, in particular, is FDA approved for attention-deficit/hyperactivity disorder (ADHD), depression, and the non-neurologic diagnosis of enuresis [57] . Additional offlabel indications include bulimia nervosa, neuropathic pain, panic disorder, and post-traumatic stress disorder [57] . Imipramine has been reported in case studies and small series as treatment for epilepsy, initially for generalized seizure types of absence and myoclonic astatic type and later for temporal lobe seizures [58] [59] [60] .
Typical imipramine doses range from 25 to 75 mg/day (not to exceed 2.5 mg/kg/day) in pediatric patients and 50 to 300 mg/day in adult patients for approved indications [57] . The MOA can be attributed to several different pathways, including increased synaptic concentration of serotonin and norepinephrine (NE) in the CNS via reuptake inhibition in the presynaptic neuronal membrane. Other potential MOAs include adenyl cyclase desensitization, down regulation of beta-adrenergic receptors, and down regulation of serotonin receptors [57]. Imipramine's antiepileptict activity is not precisely defined. Studies suggest imipramine may act similarly to ethosuximide. Corticofugal inhibition of the trigeminal nucleus is decreased and, ultimately, spreading seizure activity through subcortical pathways is prevented [59] . [61] . Finally, the pre-synaptic reuptake inhibition of NE and 5-hydroxytryptamine may contribute to antiepilepticmechanisms. Further studies are needed to precisely identify imipramine's antiepileptic effect [62] [63] [64] .
Imipramine was first reported as an efficacious treatment in patients with absence and minor motor seizures. Fromm et al. conducted an open-label study in 20 patients aged 3 to 31 years with absence, myoclonic, and/or akinetic seizures who failed to respond or became refractory to anticonvulsants such as trimethadione, ethosuximide, and diazepam [65] . Subjects initiated imipramine therapy at 30 to 40 mg/day. Doses were adjusted gradually to optimize therapy at maximum response rate or until intolerance occurred. Fifteen of twenty (75%) subjects demonstrated good initial response defined as at least 50% reduction in seizure frequency from baseline. Six (40%) maintained this response at one year. Of the 15 subjects with good initial response, the majority (n = 11)experienced 90-100% reduction [65] . A followup double-blind crossover study of imipramine demonstrated similar efficacy with doses of 0.7 to 3.5 mg/kg/day in 10 patients aged 5 to 42 years with absence and myoclonic-astatic seizures [66] . Fifty percent of participants saw significant initial decreases in seizure frequency. The open label portion included 16 patients demonstrating initial reduction of seizure frequency in 63% with a lasting effect for more than one year in 25% of patients [66] . A more recent open label study of imipramine in children with generalized epilepsy demonstrated >80% reduction in seizures in 53% of patients; 26% remained seizure free at one year. Authors reported imipramine as especially efficacious in drop attacks [60] .
Gall et al. examined imipramine for treatment of temporal lobe epilepsy [58] . In their in vitro study, hippocampal slices from Wistar rats were extracted and submerged in various solutions containing different anticonvulsants. With imipramine, seizurelike events (SLEs) were progressively reduced until complete, rapid, and irreversible suppression of epileptiform activity in all slices was observed. Both SLEs and interictal bursts were blocked with the application of imipramine. Interictal bursts were notably responsive to imipramine [58] . Other studies, however, indicate the free concentration of imipramine may not reach clinically meaningful concentrations in the CSF and would be too low to produce clinical anticonvulsant results [61] .
The only clinical experience in focal seizures comes from case reports with the imipramine derivative, clomipramine. Sakakihara et al. reported two cases of localization related epilepsy refractory to various anticonvulsant medications treated with clomipramine 20 mg/day [67] . The first patient, a 12 year-old female, had previously failed phenobarbital, VPA, zonisamide, and carbamazepine but achieved and maintained seizure freedom for nearly 18 months with clomipramine. The second patient, a 34 year-old female, saw a gradual decrease in seizure frequency over eight months from nearly 15 seizures per month to zero or one a month [67] .
Patients with epilepsy can generally utilize imipramine safely; however, there are reports of various side effects, including provocation of seizures [68] . These manifestations may result from a dosage dependent biphasic response produced by imipramine. In an early animal study by Lange et al., cats receiving "lower" doses (2.5-15 mg/kg) had diminished epileptiform discharges. Alternatively, those receiving 20 mg/kg and higher had a marked increase in seizures and production of spontaneous epileptiform episodes [69] . Others demonstrated a dose-dependent increase in EEG discharges with imipramine in rats [70, 71] . The authors suggest H1 receptor antagonism and noradrenaline activating effects of imipramine most likely contributed to the production of proconvulsant effects of imipramine -rather than cholinergic or serotonergic causes [71] . Thus, proconvulsant concerns with imipramine may, in theory, be curbed with assignment of lower dosages.
Imipramine may present an opportunity in patients with refractory epilepsy -including absence, myoclonic-astatic, and minor motor seizures. As data is lacking, utilization of imipramine should be reserved in cases where more traditional treatment options have been exhausted. Should imipramine be implemented, low doses of imipramine should be utilized to prevent any potential proconvulsant activity.
Lidocaine
Classified as a class Ib antiarrhythmic, lidocaine has historically been used in the treatment of ventricular arrhythmias and as a local or regional anesthetic. Lidocaine's antiarrhythmic properties can be attributed to its direct action on the neuronal membrane to raise the electrical stimulation threshold of the ventricle during diastole. Membrane permeability to sodium ions is decreased, leading to depolarization inhibition, and ultimately resulting in conduction blockade [72, 73] . Lidocaine utilizes a similar pathway to exert its anesthetic effects. Sodium blockade within the neuron prevents depolarization within nerve fibers resulting in impediment of pain signals to the brain [72] .
Lidocaine's exact antiepileptic mechanism is unknown, but it is likely due in part to sodium channel blockade leading to neuronal signal propagation reduction. Lidocaine pharmacokinetics should be considered given the effects and toxicities are dose dependent and affected by active metabolite production [72] . At higher concentrations, lidocaine may act as a proconvulsant, in part, due to the additive effect of the active metabolites monoethylglycinexylidide (MEGX) and glycinexylidide (GX) [74] . Antiepileptic effects are bolstered by its properties as a lipophilic amine. This allows the molecule to easily cross the blood brain barrier (BBB) and be more readily available at the site of action [75, 76] .
Lidocaine may play a special role in treating neonatal seizures where neurons and neuronal connections are still developing. The neonatal brain is much more immature than the fully formed adult brain where GABA is the major inhibitory neurotransmitter. In developing neonatal neurons, GABA exerts an excitatory mechanism [77] . AEDs such as phenobarbital utilize the inhibitory effects of GABA to control seizures which may prove problematic. Sodium channel blockage may provide an alternative MOA.
In a study by Hellström-Westras et al., lidocaine was used in 46 neonates (17 of which were preterm) who failed to respond to phenobarbital and/or diazepam [78] . Multiple methods of lidocaine dosage and administration were utilized (loading doses: 0-2 mg/kg; initial maintenance doses: 0-6 mg/kg/h), and treatment was considered successful if seizures were terminated within 3 to 4 h of initiation. An 83% response rate was recorded with the majority of patients responding to 2 mg/kg loading dose followed by a 6 mg/kg/h infusion lasting an average of 3.5 days. The treatment was well tolerated with only some moderate elevation of blood pressure reported [78] .
In a follow up study, therapeutic and toxic concentrations of lidocaine and its active metabolites, MEGX and GX, were the primary focus. A similar dosing protocol and patient population was studied [79] . While current antiarrhythmic practices utilize the therapeutic parameters (which include MEGX and GX) of 6 to 30 mmol/L to achieve therapeutic effects, therapeutic parameters have not been established in the treatment of seizures. In 24 newborns studied, only two had no anticonvulsive effects and only two had a suspected AEs. In one of these infants, MEGX, GX, and lidocaine concentrations reached the highest concentrations of all infants treated. Other infants achieved similar lidocaine concentrations without any clinically relevant AEs. Ultimately, the authors concluded measurements of lidocaine concentrations appeared to be of little clinical value except when accumulation or toxicity is suspected and advocated for limiting duration in order to limit the potential for accumulation [79] .
Sawaishi et al. reported success with lidocaine in an infant with early infantile epileptic encephalopathy and suppression burst [80] . Lidocaine was administered as a continuous infusion of 2 mg/ kg/h over eight hours with seizures ceasing at the 8 h mark. After cessation was achieved, the lidocaine dose was titrated and eventually transitioned to oral therapy to achieve a low serum concentration of 0.5 mg/L [80] . Nakano et al. reported two cases of early myoclonic encephalopathy successfully treated with lidocaine and carbamazepine using lidocaine infusions at 0.5 mg/kg/h for 35 and 50 days [81] . Malingré et al. examined a stepwise approach with lidocaine infusions in 20 neonates with seizures [82] . Lidocaine was initiated with a 2 mg/kg loading dose, followed by infusions at 6 mg/kg/h for 12 h, then 4 mg/kg/h for 12 h, and finally 2 mg/kg/h for 12 h. Efficacy was noted in 76%. Nearly 65% reached a lidocaine plasma concentration greater than 9 mg/L. No difference was seen in response when associated with a high lidocaine serum concentration. One of lidocaine's metabolites, MEGX appeared to accumulate more rapidly during the 6 mg/kg/h infusion. Given serum concentration of lidocaine and its metabolite are unlikely related to efficacy but may increase toxicity, the authors created a new regimen utilizing a shorter initial infusion duration to lower the total exposure to lidocaine and lower the serum concentration to <9 mg/L. Fifteen patients assigned this new regimen with 78% showing maintenance of efficacy, no cardiac side effects were noted, and the majority of patient's lidocaine plasma levels remained under the 9 mg/L maximum [82] . Van den Broek et al. reimagined this stepwise dosing regimen and applied it to a protocol based on patient weight. With this regimen, efficacy remained the same while lidocaine plasma concentrations were further minimized to 6 or 7 mg/L, further minimizing risk for AEs [83] .
Larger studies have examined lidocaine's safety and efficacy. Weeke et al. employed a similar, weight based, stepwise lidocaine dosing protocol as suggested by van den Broek et al. but considered temperature (normothermia and hypothermia) in the dosing protocol [83, 84] . Retrospective review of 413 pre-term and term neonates assigned lidocaine as a first, second, or third line agent was conducted. While all groups experienced seizure cessation, delayed implementation (i.e. 3rd line agent compared to 1st line) improved response. Authors suggest lidocaine (combined with midazolam) may be a viable alternative in neonatal seizures unresponsive to phenobarbital due to potential pharmacologic synergy [84] .
A ten-year, retrospective cohort review was conducted by Lundqvist et al. on term neonates receiving lidocaine as a second line AED [85] . Lidocaine doses ranged from 4 to 8 mg/kg/h with the majority receiving continuous infusion without loading doses. Infusions were maintained until therapy was considered successful (range = 11 to 60 h, median 39 h) and were subsequently tapered until discontinuation. Ultimately, 16 of 30 infants (53%) achieved seizure activity cessation clinically and on EEG. Another three (10%) showed probable response to lidocaine. Only one report of an AE -transient bradycardia -was recorded [85] .
Because mechanisms inhibiting sodium influx to control seizures are effective, lidocaine has been examined for use for treatment of SE [86, 87] . Lidocaine's use in SE is logical given quick onset of action (45-90 s) and short half-life (1.5-2 h for the parent compound; 1-6 h for MEGX; 1 h for GX) [72] . A 70% response in 10 patients receiving non-standardized IV lidocaine for SE was observed in an early case series [86] . However, a retrospective review of 37 pediatric patients and 53 SE episodes showed only 19 (35.8%) achieved seizure cessation with lidocaine. Those classified as focal appeared to have superior responses to lidocaine (46.1%) [88] . Few SE trials have been conducted. Otherwise, the majority of information reported in case reports and series have shown response rates ranging from 70 to 100% [81, 87] .
Few AEs with lidocaine use for epilepsy have been reported. Berger et al. documented a case of mydriasis with the IV lidocaine 3 mg/kg/h in an infant [89] . The lidocaine serum concentration was elevated at 9 mcg/mL and normal pupillary action was restored once serum concentrations of lidocaine were negligible [89] . A review of 521 term and preterm neonates exposed to lidocaine showed rare cardiac events -occurring in 11 of 521 patients (2.1%) [90] . In fact, a statistically significant decrease cardiac event incidence was seen in patients whom the stepwise dosing protocol was applied (1 in 246 (0.4%); p = 0.02) [90] .
Current data suggests lidocaine may be efficacious in the treatment of neonatal seizures with an acceptable safety profile. Lidocaine infusion dosing has ranged from 0.5 mg/kg/h up to 8 mg/ kg/h. Some studies have shown elevated lidocaine and metabolite serum concentrations may increase toxicity risk. To balance safety and efficacy, one should consider reduced infusion times and individualized dosing regimens based on weight and temperature. Because lidocaine still does not carry an indication for use in neonatal seizure therapy, utilization of other AEDs as first or second line is still recommended.
Stimulants
Nearly 30% of epilepsy patients have ADHD, and stimulants are often taken to improve concentration and minimize impulsivity. These symptoms may be due to the epilepsy itself, concomitant AEDs, or underlying brain dysfunction [91, 92] .
Amphetamine and its derivatives are noncatecholamine, sympathomimetic amines which promote catecholamine release (primarily dopamine and NE) in pre-synaptic nerve terminals. These also block catecholamine reuptake via competitive inhibition [93] [94] [95] [96] [97] . Methylphenidate is a milder CNS stimulant with slightly different MOA where dopamine and NE reuptake is blocked, extending the time present in the nerve synapse. Methylphenidate may present comparatively less risk for potentiating seizures than other stimulants [92] .
Gonzalez-Heydrich et al. compared methylphenidate and amphetamine in patients with epilepsy and ADHD [98] . Their retrospective study reported three instances of stimulant induced seizures (one with methylphenidate and two with amphetamine) in 36 patients. Hemmer et al. documented similar potential with methylphenidate (0.3-1 mg/kg/day) and dextroamphetamine/amphetamine salts (0.1-0.5 mg/kg/day) in patients with uncomplicated ADHD [99] . Seizure incidence was one of 175 (0.6%) in patients with nonepileptiform EEGs and three of 30 (10%) (p < 0.003) in patients with epileptiform EEGs. This supports the notion that methylphenidate may lower seizure threshold in patients with uncontrolled epilepsy [99] . It may, then, be extrapolated that other stimulants carry some risk in the setting of uncontrolled epilepsy. However, while stimulants are often discouraged in patients with epilepsy due to potential lowered seizure threshold, benefits may outweigh this potential risk in some cases. Interestingly, stimulants were historically studied for the treatment of epilepsy. "Nocturnal" seizures appeared to respond to methamphetamine and dextroamphetamine. An early study by Logothetis (1959) reported 50-100% improvement in nocturnal seizure frequency using methamphetamine sulfate 5 mg or 10 mg at bedtime [100] . Decades later, Livingston et al. reported similar findings with sustained release dextroamphetamine doses of 5 to 15 mg in children and adolescents and 15 to 25 mg in adults [101] . Later studies largely focused on methylphenidate. Marescaux et al. reported two patients with seizure improvement after methylphenidate addition dosed from 0.25-0.75 mg/kg/day [102] . Absence seizures and waking EEG abnormalities were reported to transiently remit in both patients. Marked insomnia and anorexia led to therapy cessation in both [102] .
Recent studies have strengthened early findings of methylphenidate's possible antiepileptic potential. Gucuyener et al. utilized methylphenidate for ADHD in 119 patients with epilepsy or EEG abnormalities. Methylphenidate doses of 0.3 to 1 mg/kg/day led to statistically significantly reduced active epileptiform activity from baseline to end of study (12 months) [103] . In patients with epilepsy, there was reduction in abnormal EEG findings from 35.1% to 19.3% (p = 0.01); whereas patients with abnormal EEG findings had active epileptiform activity reduced from 24.2% to 12.9%. Additionally, patients with epilepsy increased the number of patients with normal EEG findings from baseline to end of study (3.5% to 14%, p = 0.02) [103] . Seizure response to methylphenidate addition was not examined, but only 5 (4.2%) patients had increased seizure frequency (lower than that suggested by Hemmer et al.) [93, 103] .
Radzuik et al. reported statistically significant improvements in seizure frequency and severity among patients with various epilepsies (generalized, partial, and unknown/idiopathic) with methylphenidate (0.13 to 0.8 mg/kg/day; mean = 0.39 AE 0.18 mg/ kg/day) [104] . Seizure frequency and severity were assessed three months prior to initiation of methylphenidate (T-3) (during which time each patient's current AED regimen was optimized), at methylphenidate initiation (T0), one month after initiation (T + 1), and three months after initiation (T + 3). From baseline to T0, monthly seizure frequency was reduced from 6.5 to 2 in response to changes in the patients AEDs. From addition of methylphenidate to T + 1, seizure frequency was further reduced to 0 and persisted to T + 3 [104] . Seizure severity was assessed employing parent surveys utilizing the Hague Seizure Severity Scale (HASS) (HASS scale: 13 = no seizures, 52 = maximum severity) [105] . Baseline severity was recorded at 29, reduced to 24 at T0, further decreased to 13 at T + 1 and was maintained at T + 3 [104] .
Overall, stimulant utilization in the treatment of epilepsy and seizures is conflicted and data is limited. Data suggests lowered seizure threshold in a small proportion of patients with epilepsy, but historical success in reduction of EEG abnormalities and seizure frequency is notable Success has appeared transient and side effects sometimes limiting, though more recent success with methylphenidate is more promising. As a result, larger safety and efficacy studies would be needed to further define the role of methylphenidate or other stimulants in current seizure treatment practices.
Verapamil
Calcium channel blockers are frequently used for treatment of arrhythmias, angina, and hypertension. This class of drug is divided into dihydropyridines and non-dihydropyridines. Dihydropyridines such as nifedipine and amlodipine are potent vasodilators that have little to no negative effect on cardiac contractility or conduction, while non-dihydropyridines such as verapamil have less potency as a vasodilator but have a greater extent of depressing contractility and conduction [106, 107] .
Verapamil is a potential treatment for epilepsy with multiple MOA. Excitatory amino acid receptor activation induces calcium movement across neuronal membranes. Calcium ions influx has been associated with epileptiform bursts whereas a decrease in extracellular calcium concentrations precedes seizure onset in several epilepsy models [107] [108] [109] [110] [111] . Verapamil reversibly blocks transmembraneous calcium flux during epileptic discharges resulting in dampened epileptic effect [112] . Additionally, verapamil's lipophilic nature aids ability reach appropriate sites of action by crossing the BBB [113] . It has also been postulated Pglycoprotein (P-gp) plays a role in refractory seizure disorders via over-expression in the BBB of epileptic foci and efflux of AEDs [114] [115] [116] [117] . Over-expression may effectively result in inadequate AED concentrations at the site of action. Verapamil, a non-selective P-gp inhibitor, reduces AED efflux from the brain and may increase the concentration at the epileptic foci [118] [119] [120] [121] . Finally, verapamil inhibits cytochrome p450 which could increase AED serum concentrations further improving seizure control [106] .
Exploration of verapamil's potential in epilepsy began with animal studies. Speckmann et al. demonstrated calcium current reduction in a single snail neuron with verapamil [122] . Studies of kainic acid and quinolinic acid-induced seizures in rats demonstrated intraperitoneal verapamil 40 mg/kg reduced total number of quinolinic acid-induced seizures by 88%. No effect was seen with verapamil 20 mg/kg or in kainic acid-induced seizures [123] . Intraventricular verapamil was shown to terminate epileptic EEG potentials which returned when verapamil was discontinued; additional studies showed efficacy in treatment of GTC seizures and focal epileptiform discharges [122, 124, 125] .
Human experience with verapamil as an antiepileptic agent includes case reports and small series. Several noted efficacy for localization related epilepsy. Summers et al. noted a widened interval between episodes of SE with verapamil initiated at 180 mg/day and increased to 480 mg/day in a 24 year old patient with focal onset seizures and recurrent SE [126] . Schmitt et al. reported statistically significant nocturnal seizure reduction over a relatively short period of 15 days in a 20 year-old patient with frontal lobe epilepsy, bilateral tonic clonic seizures, and tonic refractory SE treated with 120 mg/day [127] . Pirker et al. reported an 80 year-old woman with refractory focal clonic seizures who previously failed multiple AEDs before achieving seizure control with a combination of carbamazepine, clobazam, and verapamil initiated at 40 mg and gradually increased to 120 mg/day [128] . An eight week pilot study with adjunct verapamil in 19 patients with refractory temporal lobe epilepsy was performed by Asadi-Pooya et al. [129] . Thirteen of 19 patients received verapamil 120 mg/day and six received 240 mg/day. Patients were deemed responders if a 50% reduction in seizure frequency was observed at the end of the study period. Seven of the 19 patients (36.84%) were responders. Fifty percent of patients receiving verapamil 240 mg/day were designated as "responders" suggesting a dose effect. More importantly, amongst high dose responders, two were seizure free and one had a greater than 95% reduction in seizures. In contrast, only four of 13 patients (30.7%) receiving verapamil 120 mg/day were classified as "responders". No reported AEs led to verapamil discontinuation, but, in some cases, complaints of diplopia and vertigo led to dose reductions. Mild AEs (i.e. constipation, palpitation, nausea, and dyspnea) were reported in most patients, but were limited to the titration period [129] .
Narayanan et al. reported success with lower doses of verapamil (60 mg/day) in 19 adult patients with localization-related epilepsy (n = 14), Lennox Gastaut Syndrome (LGS) (n = 4), and combinations of generalized and focal epilepsy (n = 1) [130] . Ten of 19 patients (53%) had >50% reduction in seizure frequency, two (10%) experienced up to 50% reduction, and the remaining seven patients did not experience any seizure reduction. Interestingly, all LGS patients showed some response to verapamil therapy -75% had 50% or greater seizure frequency reduction and 25% showed <50% response [130] . Side effects were mild and included upset stomach, lightheadedness, increased fatigue, and agitation. Upset stomach, lightheadedness, and increased fatigue resolved once the verapamil was adjusted to take with meals or staggered with concomitant AEDs. No patient reported any cardiac or hemodynamic side effects (aside from lightheadedness) [130] .
Experience in pediatric populations with generalized and focal onset epilepsies has also been reported. Iannetti et al. described their experience with verapamil 1 to 1.5 mg/kg/day in two patients with severe myoclonic epilepsy of infancy (SMEI) [131] . One patient responded well and maintained response for 13 months. Verapamil was discontinued and seizures returned. The second patient experienced decreased myoclonias which was maintained during the 20 month follow-up period. Focal and generalized seizures persisted [131] . Wical et al. trialed oral verapamil 4 to 8 mg/kg/day in five patients aged 3 to 18 years with GTC and focal onset seizures with secondary generalization. Only one patient did not show response; the remaining four showed 40-80% seizure reduction [132] .
Not all reports with verapamil have produced positive results. Nicita et al. reported little success with verapamil use in seven patients with SMEI, LGS, or symptomatic epilepsy [133] . Patients were given oral verapamil dosed 1 to 1.5 mg/kg/day. Three of four patients with SMEI partially responded while the remaining patients had only a brief period of seizure control [133] . A single center, double-blind pilot study examined the adjuvant use of verapamil in refractory seizures [134] . Patients must have been on at least one AED that is a substrate for P-gp (i.e. carbamazepine, phenytoin, lamotrigine, VPA, phenobarbital, primidone, gabapentin, levetiracetam, or topiramate) and were randomized to either placebo or verapamil 80-240 mg daily. Twenty-two patients were initially randomized; only 12 patients completed the study (four withdrew due to side effects; five withdrew soon after consent was obtained with no exposure to either treatment arm; one passed away after consent but prior to verapamil exposure). No one completing the study reached at least 50% seizure frequency reduction. There was no significant difference between verapamil and placebo in the double blind or open label study (p = 0.41 and p = 0.98, respectively) despite the fact carbamazepine, VPA, and clobazam levels increased with concomitant use of verapamil [134] .
Verapamil may be an option in refractory epilepsies with both focal and generalized seizure types. Based on limited data, response appears to be dose-dependent, but benefit must be weighed against side effects with higher dosing. It may be wise to initiate low dose therapy and titrate to effect and tolerability. Dosing with meals or around concomitant therapy may deter side effect emergence. Larger randomized controlled trials are warranted.
Conclusion
Nearly one third of epilepsy patients will be intractable to initial medical therapy. While a proportion of these patients may be candidates for surgical therapy, others are not and must pursue alternative treatments. Most neurologists encounter a patient who failed all commonly approved therapies for epilepsy. This group of patients is notoriously difficult to manage, and lesser known approaches must be utilized to achieve seizure control.
Numerous medications initially intended to treat other diseases have shown promise in epilepsy treatment and should be considered when traditional AEDs fail. Some (i.e. acetazolamide, lidocaine, verapamil) have MOAs similar to existing therapies, while others (i.e. amantadine, bumetanide, imipramine, stimulants) offer novel mechanistic approaches to seizure control. Many medications presented have enough accumulated evidence to make them viable treatment options. Others are less likely to provide value. Of the drugs reviewed, lidocaine has the largest reported patient exposure and appears especially efficacious for acute onset neonatal seizures when infused continuously. Lidocaine appears appropriate for use as at least a 3rd line agent in refractory neonatal seizures with efficacy balanced against side effects, including proconvulsant effects, at high levels. Conceptually, bumetanide's MOA makes it an attractive option in neonatal epilepsy treatment, but mounting evidence suggests it may only be worth considering in desperate situations given minimal reported efficacy. Prodrugs of bumetanide, however, may hold favorable potential and deserve more study.
Amantadine and imipramine show great promise in refractory absence seizures and should be considered when ethosuximide, VPA, and lamotrigine fail. The fact these drugs also treat ADHD, a common comorbidity of absence epilepsy, is an added benefit. Imipramine is also an attractive option for treatment of atonic seizures which are often refractory to medical treatment. Caution must be used to avoid proconvulsant effects at higher dosing. Despite less robust reports of efficacy, acetazolamide should also be considered for treatment of intractable generalized seizures. Notably, mild side effects may be exacerbated when used along with other AEDs with carbonic anhydrase mechanisms.
Finally, verapamil and stimulants have little evidence to make firm recommendations. Verapamil may be efficacious for focal onset seizures, but dose-related AEs may limit use of high doses which are more often associated with efficacy. Stimulants, on the other hand, have very little evidence to suggest efficacy in refractory epilepsy. At best, the proconvulsant potential of stimulants is minimal. It is reasonable to utilize them in patients with refractory epilepsy and comorbid ADHD with the hopes seizure frequency may improve while treating behavior.
We have reviewed the available data on several alternative options for treatment of intractable epilepsy including potential MOAs, characteristics of patient exposures, efficacy, and safety in those populations. Many medications have adequate data to deem them viable treatment options for patients refractory to traditional AEDs. For others, their MOA or limited patient experience provides enough impetus to study them further in hopes of finding additional therapeutic options for the treatment of epilepsy.
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